Advanced Squamous Non-Small Cell Lung Cancer: Case 1 Advanced Squamous Non-Small Cell Lung Cancer
November 2016
An 81-year-old male presents to his physician with symptoms of cough, hemoptysis, and fatigue requiring frequent rest during the day PMH includes hypercholesterolemia, controlled on simvastatin and hypertension, controlled on a calcium channel blocker; mild osteoarthritis He has no history of smoking The patient is physically active and plays golf several days per week CT of the chest revealed a solid cystic mass in the left upper lobe and lymphadenopathy in the left hilar and bilateral mediastinal nodes PET/CT imaging showed 18F-FDG uptake in the lung mass, left hilar and both mediastinal lymph nodes Bronchoscopy and transbronchial lung biopsy were performed Pathology showed grade 3 squamous cell carcinoma of the lung Genetic testing was negative for known driver mutations PD-L1 testing by IHC showed expression in 65% of cells The patient was started on therapy with pembrolizumab Follow up imaging at 3 months showed stable disease
April 2017
After 5 months on immunotherapy, the patient was hospitalized after having a seizure. He reported worsening fatigue and cough for 1 month CT showed increased size of the left upper lobe pulmonary mass Brain imaging showed several small intracranial lesions WBRT was started Immunotherapy was discontinued and the patient was started on carboplatin and nab-paclitaxel Newsletter Stay up to date on practice-changing data in community practice.
Subscribe
September 17th, 2026 The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
September 21st, 2026 Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
September 17th, 2026 The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
September 25th, 2026 US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.
September 19th, 2026 David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.